#Molecular Diagnostics

[pathologylab]

Join us at #Medlab Asia 2024, from July 10–12, at the Queen Sirikit National Convention Center in Bangkok. We are excited to participate in this event, showcasing our innovative product portfolio, which includes RT-PCR #IVD kits, nucleic #acid extraction solutions, #NGS clinical panels, and point-of-care #testing solutions.

Don’t miss the opportunity to visit #G2M's booth at #MedlabAisa 2024. We look forward to meeting you, sharing insights, and exploring collaboration opportunities.

Let's set new benchmarks in the diagnostic space together!

🌍 Book Your Meeting Slot: https://www.genes2me.com/upcoming-events

📅 Medlab Asia - 10th to 12th July 2024

🎯 Queen Sirikit National Convention Center - Bangkok

🏗 Booth No. H6.C19

#MedlabAsia2024 #HealthcareInnovation #MolecularDiagnostics #nucleicacid #extraction #asia #medlabasia #solutions #molecular #panels #clinical #testing #rtpcr #poc #poct

#Medlab #medlab asia #panels #medlab asia 2024 #bangkok #molecular diagnostics #health care #asia #solutions #nucleic acid #molecular

[markettrends1234]

Animal Health Diagnostics Market 2024-2028: Pet Humanization Drives Growth with 10.38% CAGR

Accompany Technavio as we delve into the evolving relationship between pets and their human families, revealing the thriving growth of the Animal Health Diagnostics Market. Anticipate a remarkable USD 2.46 billion expansion and an enticing 10.38% CAGR from 2023 to 2028, propelled by the increasing phenomenon of pet humanization. With pets becoming increasingly integrated into households, diagnostic tests emerge as indispensable tools for proactive healthcare, safeguarding against potential health concerns.

#Veterinary Medicine #Animal Health #Diagnostics #Veterinary Diagnostics #Infectious Diseases #Animal Wellness #Point-of-Care Testing #Molecular Diagnostics

[market-insider]

Unraveling the Intricacies of the Molecular Diagnostics Market and its Future Prospects

The global molecular diagnostics market size is expected to reach USD 17.97 billion by 2030, and expanding at a CAGR of 4.5% from 2024 to 2030, according to a recent study by Grand View Research, Inc. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.

Molecular Diagnostics Market Report Highlights

The reagents segment dominated the market and accounted for a share of 62.2% of the global revenue in 2023. It is expected to maintain its dominance throughout the forecast years owing to its wide application scope in research & clinical settings and increasing adoption of novel tests.

The polymerase chain reaction technology segment accounted for the largest revenue share in 2023. This is attributed to its use in detecting COVID-19 and other infectious diseases.

The infectious diseases segment accounted for the largest revenue share in 2023. The increased usage of molecular, particularly PCR tests, for diagnosing COVID-19 has increased the segment share significantly.

The central laboratories segment dominated the industry in 2023 owing to high procedure volumes for COVID testing and other healthcare indications in central laboratories.

North America dominated the market and accounted for a 39.3% share in 2023. This is attributed to the rising epidemiology of infectious as well as chronic diseases, thus, encouraging companies to introduce novel molecular diagnostic tests, thereby boosting market growth.

Asia Pacific is anticipated to exhibit significant growth from 2024 to 2030 owing to increased market penetration, initiatives of local market players to increase the adoption of novel diagnostic technologies, and high unmet market needs.

For More Details or Sample Copy please visit link @: Molecular Diagnostics Market Report

Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.

Companies are expanding their product portfolios with the acquisition of smaller companies. For instance, in March 2021, Hologic announced the acquisition of Diagenode-a molecular diagnostic company with a wide range of PCR instruments, facilitating the detection of over 30 bacteria-for USD 159 million. Similarly, in April 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics, Inc. at a price of USD 24.05 per share in cash, and it holds around 82.89% of total shares of GenMark Diagnostics. GenMark Diagnostics, Inc. has proprietary technologies, such as eSensor XT-8 and ePlex, which can be utilized in developing tests for infectious diseases, including bloodstream infections.

#MolecularDiagnostics #PrecisionMedicine #HealthcareInnovation #GenomicTesting #DiagnosticsTechnology #Biotechnology #PersonalizedMedicine #DiagnosticRevolution #NGS #BiomarkerDiscovery #InfectiousDiseaseDiagnosis #CancerDetection #Theranostics #Bioinformatics #MolecularBiology #DiagnosticTrends #MedicalTechnology #LaboratoryTesting #PointofCareDiagnostics #HealthTechInnovation

#Molecular Diagnostics #Precision Medicine #Healthcare Innovation #Genomic Testing #Diagnostics Technology #Biotechnology #Personalized Medicine #Diagnostic Revolution #NGS #Next Generation Sequencing #Biomarker Discovery #Infectious Disease Diagnosis #Cancer Detection #Theranostics #Bioinformatics #Molecular Biology

[cleartalefestival]

THE BEST DIAGNOSTIC , PATHOLOGY & DOCTOR'S CENTER IN KOLKATA

As the top pathology facility in the city of Kolkata, Max Care Pathology Center has become the benchmark for superiority in medical diagnostics. With a dedication to accuracy, dependability, and patient-centered service, Max Care has become the go-to option for anyone looking for top-notch pathology services in the city . Modern technology and a group of expert pathologists work together at Max Care to deliver precise and rapid results. Modern diagnostic tools are available at the center, guaranteeing the highest level of accuracy in testing and evaluations. For a variety of pathology services, including blood tests, urine analysis, biopsy evaluations, and specialist diagnostic procedures, patients may rely on Max Care . Max Care stands out for its steadfast commitment to the welfare of its patients. The personnel is renowned for their kindness, professionalism, and dedication to providing results as quickly as possible . The facility upholds the highest moral standards in the business and guarantees full secrecy and privacy of patient information .One further characteristic of Max Care is convenience. It is easily accessible to a large cross-section of the community thanks to its many branches throughout Kolkata. Max Care also provides online appointment scheduling and reporting services, making it simpler for patients to plan visits and receive test results from the convenience of their homes . In conclusion, Kolkata's Max Care Pathology Center is the pinnacle of competence in the diagnostics industry. It is the finest option for anyone looking for top-notch pathology services in the city thanks to its cutting-edge technology, knowledgeable staff, dedication to patient care, and accessibility. One precise diagnosis at a time, Max Care is committed to enhancing the health and well-being of the communities it serves .

Pathological Center .

Pathology Services .

Medical Laboratory .

Diagnostic Center .

Clinical Pathology .

Histo pathology .

Blood Testing .

Biopsy Services .

Molecular Diagnostics .

Pathology Lab .

Cyto pathology .

Pathologist Doctors .

Disease Diagnosis .

Laboratory Tests .

Pathological Testing .

Immuno histo chemistry .

Pathology Report .

Medical Testing .

Microscopic Analysis .

Pathology Consultation .

Clinical Diagnostics .

Medical Pathology .

Hemato pathology .

Cancer Diagnosis .

#Pathology #Pathologist #Medical Lab #Diagnostic Center #Health care #Disease Diagnosis #Medical Testing #Lab Tests #Clinical Pathology #Histo pathology #Cancer Screening #Molecular Diagnostics #Clinical Diagnostics #Pathology Services #Pathology Lab #Specimen Analysis #Biopsy #Immuno histo chemistry #Cytology #Hemato pathology #Cellular Pathology #Medical Pathology #Pathology Report #Health And Wellness #Medical Science #Wellness Wednesday #Healthy Living #Disease Prevention #Patient Care

[delvens-blog]

#Molecular Diagnostics Market #Molecular Diagnostics #Molecular Diagnostics Market Size #Molecular Diagnostics Market Share #Molecular Diagnostics Market Growth #Molecular Diagnostics Market Trends #Molecular Diagnostics Market Overview #Molecular Diagnostics Market 2023 #healthcare

[karanblog103]

Molecular Diagnostics Market to Hit 12.1% CAGR: 2028 Projections Led by Infectious Diseases Segment

#Molecular Diagnostics

[adityarana1687-blog]

Molecular Diagnostics Market Expected To Achieve Lucrative Growth By 2030

The global molecular diagnostics market size is expected to reach USD 31.9 billion by 2030, and is expected to decline at a CAGR of -1.6% from 2022 to 2030, according to a recent study by Grand View Research, Inc. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.

Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.

Companies are expanding their product portfolios with the acquisition of smaller companies. For instance, in March 2021, Hologic announced the acquisition of Diagenode-a molecular diagnostic company with a wide range of PCR instruments, facilitating the detection of over 30 bacteria-for USD 159 million. Similarly, in April 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics, Inc. at a price of USD 24.05 per share in cash, and it holds around 82.89% of total shares of GenMark Diagnostics. GenMark Diagnostics, Inc. has proprietary technologies, such as eSensor XT-8 and ePlex, which can be utilized in developing tests for infectious diseases, including bloodstream infections.

Key players are enhancing their range of testing options for real-time PCR instruments by increasing R&D activities for the development of kits that target emerging diseases or by entering into agreements with other kit manufacturing companies. These include the introduction of Cobas HPV test assay in Cobas 4800 by Roche Diagnostics. The introduction of tuberculosis testing Xpert assay on GeneXpert platform by Cepheid is an example of such advancement. Such advances are anticipated to drive the global molecular diagnostics market.

Request a free sample copy or view report summary: Molecular Diagnostics Market Report

Molecular Diagnostics Market Report Highlights

Reagents dominated the overall market majorly driven by the high usage rate of reagents due to the COVID-19 pandemic

PCR technology accounted for a revenue share of 64.6% in 2021. The increased use of PCR for the diagnosis of COVID-19 and other infectious diseases is one of the major reasons for its dominance

Self-testing or OTC segment is anticipated to be the fastest-growing segment, over the forecast period, as it facilitates early diagnosis and constant patient monitoring. The launch of COVID-19 molecular self-tests is also expected to boost the growth of this segment.

North America commanded the highest revenue share in 2021, driven by a high disease prevalence, proactive government measures, high testing rate for COVID-19, technological advancements, and improvements in healthcare infrastructure.

Molecular Diagnostics Market Segmentation

For this report, Grand View Research has segmented the global molecular diagnostics market based on product, test location, technology, application, and region:

Product Outlook (Revenue, USD Million, 2017 - 2030)

Instruments

Reagents

Others

Test Location Outlook (Revenue, USD Million, 2017 - 2030)

Point-of-Care

Self-test or Over the Counter

Central Laboratories

Technology Outlook (Revenue, USD Million, 2017 - 2030)

Polymerase chain reaction (PCR)

PCR, by Type

Multiplex PCR

Other PCR

PCR, by Product

Instruments

Reagents

Others

In Situ Hybridization (ISH)

Instruments

Reagents

Others

Isothermal Nucleic Acid Amplification Technology (INAAT)

Instruments

Reagents

Others

Chips and Microarrays

Instruments

Reagents

Others

Mass Spectrometry

Instruments

Reagents

Others

Sequencing

Instruments

Reagents

Others

Transcription Mediated Amplification (TMA)

Instruments

Reagents

Others

Others

Instruments

Reagents

Others

Application Outlook (Revenue, USD Million, 2017 - 2030)

Oncology

Breast Cancer

Prostate Cancer

Colorectal Cancer

Cervical Cancer

Kidney Cancer

Liver Cancer

Blood Cancer

Lung Cancer

Other Cancer

Pharmacogenomics

Infectious Diseases

Methicillin-resistant Staphylococcus Aureus (MRSA)

Clostridium Difficile

Vancomycin-resistant Enterococci (VRE)

Carbapenem-resistant Bacteria

Flu

Respiratory Syncytial Virus (RSV)

Candida

Tuberculosis and Drug-resistant TBA

Meningitis

Gastrointestinal Panel Testing

Chlamydia

Gonorrhea

HIV

Hepatitis C

Hepatitis B

Other Infectious Disease

Genetic Testing

Newborn Screening

Predictive and Presymptomatic Testing

Other Genetic Testing

Neurological Disease

Cardiovascular Disease

Microbiology

Others

Regional Outlook (Revenue, USD Million, 2017 - 2030)

North America

U.S.

Canada

Europe

U.K.

Germany

France

Italy

Spain

Belgium

Switzerland

Netherlands

Poland

Austria

Greece

Sweden

Turkey

Finland

Asia Pacific

Japan

China

India

Sri Lanka

Malaysia

Australia

New Zealand

Thailand

Vietnam

Singapore

Latin America

Brazil

Mexico

Chile

Peru

Colombia

Argentina

Middle East & Africa

South Africa

Saudi Arabia

Jordan

UAE

Qatar

Nigeria

Egypt

#molecular diagnostics

[bisresearchreports]

Molecular diagnostics is described as diagnostic test that identifies variations in genes, ribonucleic acids (RNAs), and proteins that highlight whether a person is susceptible to a specific disease or is diagnosed with that disease. The molecular diagnostics market has made significant strides in the research, which has enabled the dissemination of treatment that has revolutionized the healthcare sector.

#Molecular Diagnostics Market #Molecular Diagnostics Market report #Molecular Diagnostics industry #Molecular Diagnostics

[science-sculpt]

ELISA: A Powerful Tool for Detecting the Invisible

ELISA, or Enzyme-Linked Immunosorbent Assay, has become a cornerstone of medical diagnostics and biological research. This versatile technique allows scientists to detect and quantify minute amounts of target molecules, such as proteins, antibodies, and even viruses, with remarkable accuracy. In this blog, we'll delve into the world of ELISA, exploring its various types, its applications, and the exciting future directions this technology holds.

At its core, ELISA relies on the exquisite specificity of antibodies. Antibodies are highly specialized proteins produced by the immune system in response to foreign invaders. Each antibody can bind to a unique structure, called an antigen, on a specific molecule. In an ELISA, scientists leverage this binding property to create a sensitive detection system.

The 1960s witnessed a surge in interest in immunoassays, techniques that utilize the specificity of antibodies to detect target molecules. One such technique, radioimmunoassay (RIA), developed by Rosalyn Yalow and Solomon Berson, revolutionized medical diagnostics. RIA used radioactively labeled antibodies to detect antigens, offering high sensitivity. However, concerns regarding the safety of radioactive materials fueled the search for a safer alternative. The year 1971 marked a turning point. Independently, Eva Engvall and Peter Perlmann published their work on a novel technique – the enzyme-linked immunosorbent assay (ELISA). ELISA replaced radioactive labels with enzymes, eliminating the safety concerns associated with RIA. Like RIA, ELISA harnessed the specific binding between antibodies and antigens. However, it employed enzymes that could generate a detectable signal, such as a color change, upon interacting with a substrate. This innovation paved the way for a safer and more user-friendly diagnostic tool.

The basic ELISA protocol involves immobilizing the target antigen on a solid surface like a plate well. Then, a sample containing the molecule of interest (e.g., a suspected virus) is introduced. If the target molecule is present, it will bind to the immobilized antigen. Next, an antibody specific to the target molecule, linked to an enzyme, is introduced. This "detection antibody" binds to the target molecule already attached to the antigen. Finally, a substrate specific to the enzyme is added. This antigen-antibody binding is visualized using an enzyme linked to a reporter molecule. When the enzyme encounters its substrate, a detectable signal is produced, such as a color change or luminescence. The intensity of this signal is directly proportional to the amount of antigen present in the sample, allowing for quantification. The beauty of ELISA lies in its adaptability. Several variations exist, each tailored for specific detection needs.

The Four Main ELISA Formats are:

Direct ELISA: Simplicity at its finest. In this format, the antigen is directly coated onto the ELISA plate. A labeled antibody specific to the antigen is then introduced, binding directly to its target. After washing away unbound molecules, the enzyme linked to the antibody generates a signal upon addition of the substrate. Direct ELISA offers a rapid and straightforward approach, but sensitivity can be lower compared to other formats due to the lack of amplification.

Indirect ELISA: Unveiling the Power of Amplification. Similar to the direct ELISA, the antigen is first coated onto the plate. However, instead of a labeled primary antibody, an unlabeled one specific to the antigen is used. This is followed by the introduction of a labeled secondary antibody that recognizes the species (e.g., mouse, rabbit) of the primary antibody. This two-step approach acts as an amplification strategy, significantly enhancing the signal compared to the direct ELISA. However, the presence of an extra incubation step and the potential for cross-reactivity with the secondary antibody add complexity.

Sandwich ELISA: Capturing the Antigen Between Two Antibodies. Here, the capture antibody, specific for one region of the antigen, is pre-coated onto the ELISA plate. The sample containing the antigen is then introduced, allowing it to be "sandwiched" between the capture antibody and a detection antibody specific for a different region of the same antigen. A labeled secondary antibody or a labeled detection antibody itself can then be used to generate the signal. Sandwich ELISA boasts high sensitivity due to the double-antibody recognition and is often the preferred format for quantifying analytes.

Competitive ELISA: A Race for Binding Sites. In this format, the antigen competes with a labeled antigen (usually a known amount) for binding sites on a capture antibody pre-coated onto the plate. The more antigen present in the sample, the less labeled antigen can bind to the capture antibody. Following a washing step, the amount of bound labeled antigen is measured, providing an inverse relationship between the signal and the concentration of antigen in the sample. Competitive ELISA is particularly useful for studying small molecules that may be difficult to directly conjugate to an enzyme.

ELISA's Reach: From Diagnostics to Research. The applications of ELISA are as vast as they are impressive. Let's delve into some key areas where ELISA plays a vital role:

Unveiling the Mysteries of Disease: Diagnostics: ELISA is a cornerstone of diagnosing infectious diseases like HIV, Hepatitis, and Lyme disease. It detects antibodies produced by the body in response to the invading pathogen, providing valuable information for early detection and treatment. Monitoring Autoimmune Diseases: ELISA helps monitor autoimmune diseases like rheumatoid arthritis and lupus by measuring specific antibodies associated with these conditions. Cancer Screening: Certain cancers can be detected by identifying tumor markers, proteins elevated in the blood of cancer patients. ELISA assays are being developed to detect these markers for early cancer screening.

Safeguarding Food Quality: Allergen Detection: Food allergies can be life-threatening. ELISA ensures food safety by enabling the detection of allergens like peanuts, gluten, and milk in food products, protecting consumers with allergies. Monitoring Foodborne Pathogens: ELISA can identify harmful bacteria, viruses, and toxins in food, preventing outbreaks of foodborne illnesses.

Environmental Monitoring: Pollutant Detection: ELISA can detect pollutants like pesticides and herbicides in water and soil samples, contributing to environmental protection efforts. Microbial Analysis: This technique can be used to identify and quantify specific microbes in environmental samples, providing insights into ecosystem health.

Research and Development: ELISA plays a crucial role in various research fields: Drug Discovery: It helps researchers assess the effectiveness of new drugs by measuring drug-target interactions and monitoring drug levels in the body. Vaccine Development: ELISA is instrumental in developing vaccines by evaluating immune responses to vaccine candidates. Basic Research: Scientists use ELISA to study various biological processes by detecting and quantifying specific molecules involved in these processes.

Despite its established role, ELISA is evolving alongside technological advancements. New multiplex platforms allow for the simultaneous detection of various targets in a single sample, boosting efficiency in biomarker discovery and disease analysis. Automation streamlines workflows minimizes errors, and increases throughput, making high-throughput screening feasible in drug development and clinical settings. Miniaturization and portable devices enable rapid on-site diagnostics, providing healthcare professionals with real-time data for quicker interventions. Additionally, ongoing research is improving assay sensitivity, reducing background noise, and expanding detection limits, allowing for the identification of trace analytes and early disease biomarkers with greater accuracy than ever before. Integration of ELISA with emerging technologies such as microfluidics, nanotechnology, and artificial intelligence holds promise for enhancing assay performance, scalability, and data analysis capabilities.

These advancements hold promise for even wider applications of ELISA in the future. ELISA has revolutionized our ability to detect and quantify biological molecules. Its versatility, accuracy, and adaptability make it an invaluable tool across various scientific disciplines. As research continues to refine and innovate ELISA techniques, we can expect even more exciting possibilities to emerge in the years to come. ELISA's future is bright, promising to play a pivotal role in unraveling the mysteries of the biological world and improving human health.

#science sculpt #life science #molecular biology #science #biology #artists on tumblr #ELISA #immunology #immunotherapy #diagnostic management software #diagnosticimaging #history of immunology #scientific advancements #biotechnology #scientific research #scientific equipment #scientific instruments #techniques in biotechnology #scientific illustration #lab equipment #sciencenature #laboratory #lab skills #molecular diagnostics market

[pathologylab]

We’re thrilled to announce our participation in #ADLM 2024, Chicago, from July 30–August 1, 2024. Visit us to explore our groundbreaking #molecular diagnostic solutions for Real-Time #PCR, nucleic acid extraction, point-of-care #testing and #NGS clinical panels.

Join us at this event to witness the future of diagnostics with G2M's cutting-edge products that can revolutionize the diagnostic healthcare industry.

#participation #india #g2m #genes2me #chicago #rtpcr #poc #clinicalpanels #healthcare #diagnostics #ADLM2024 #HealthcareInnovation #MolecularDiagnostics

#adlm #adlm 2024 #molecular #molecular diagnostics #molecular biology #g2m #genes2me #rt pcr #pcr #poc #poct #clinical panels

[burikumu]

Week Recap (Nov. 27 - Dec. 3, 2022)

Part 1

Beginning of Microbiology section

Tried to study for the week (Except on thursday siniksik ba naman yung lab sa finals week edi sana nagrereview kami diba)

Crammed the rest of the subjects the night before finals

Didn't finish reading and woke up with a headache during finals

Already on the acceptance stage even if the grades are not out yet

┈┈┈┈․° ☣ °․┈┈┈┈

Part 2

#1st sem #medtech #mls #medical technology #medical laboratory science #studyblr #medblr #uniblr #schoolblr #college #university #final exams #molecular biology and diagnostics #Clinical bacteriology #microbiology #hematology #clinical chemistry #histopathology #dec 2022

[market-insider]

Liquid Biopsy: Evolving Trends in Breast Cancer

The global breast cancer liquid biopsy market size is expected to reach USD 1.7 billion by 2030, expandingat a CAGR of 22.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth. With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment.

Breast Cancer Liquid Biopsy Market Report Highlights

In 2021, the circulating tumor cells segment held a dominant revenue share owing to the effectiveness and precision offered by CTCs in the detection of cancer

The early detection segment is projected to grow at the fastest CAGR over the forecast period, owing to the increasing adoption of liquid biopsy in early diagnosis of cancer and the rising need to provide effective treatment

Treatment selection was the highest revenue-generating segment in 2021 owing to the availability of a high number of products that aid treatment selection

Asia Pacific is expected to witness the fastest growth during the forecast period owing to increasing prevalence, improving healthcare infrastructure, and growing population

Gain deeper insights on the market and receive your free copy with TOC now @: Breast Cancer Liquid Biopsy Market Report

There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

#Breast Cancer #Liquid Biopsy #Cancer Detection #Biomarkers #Medical Diagnosis #Precision Medicine #Cancer Screening #Tumor Markers #Molecular Diagnostics #Healthcare Technology #Cancer Research #Liquid Biopsy Market #Oncology #Personalized Medicine #Biotechnology

[researchinsights]

The latest report by Precision Business Insights, titled Respiratory Molecular Diagnostics Market covers complete information on market size, share, growth, trends, segment analysis, key players, drivers, and restraints.

#Respiratory Molecular Diagnostics Market

[rahulp3]

Point-of-care Molecular Diagnostics Market Outlook (2023 to 2033)

The Global Point-of-care Molecular Diagnostics Industry is on track for a significant surge, fueled by the increasing demand for faster and more convenient diagnostic solutions. According to a recent analysis by Future Market Insights (FMI), the market is projected to reach an impressive US$11.1 billion by 2033, reflecting a remarkable growth trajectory from its estimated valuation of US$4.4 billion in 2023. This phenomenal rise signifies a Compound Annual Growth Rate (CAGR) of 9.7% over the next decade, highlighting the growing adoption of point-of-care molecular diagnostics across various healthcare settings.

The escalating prevalence of infectious and chronic diseases, encompassing cardiovascular ailments, diabetes, and the ongoing challenges posed by COVID-19, is driving a surge in the adoption of point-of-care molecular diagnostics. In response to the critical need for timely and cost-effective testing, the market is witnessing an unprecedented demand for these advanced diagnostics solutions.

Request a Sample of this Report Now Use Work Email To Get Quick Reply!https://www.futuremarketinsights.com/reports/sample/rep-gb-14279

#Global Point-of-care Molecular Diagnostics Industry

[joeymoore25]

#Oncology Molecular Diagnostics Market #imarc group

[alicetleibowitz]

Discover the transformative potential of Molecular Diagnostics, where precision meets healthcare, shaping personalized treatment pathways and revolutionizing disease detection.

#Molecular Diagnostics Market #Molecular Diagnostics Industry #Molecular Diagnostics Market size #Molecular Diagnostics Market share #Molecular Diagnostics Market demands #Molecular Diagnostics Market growth